Transportation, (734) 214–4131, or by email at *macallister.julia@epa.gov*.

Dated: November 7, 2001.

Jeffrev R. Holmstead,

Assistant Administrator, Office of Air and Radiation.

[FR Doc. 01–28522 Filed 11–13–01; 8:45 am] BILLING CODE 6560–50–P

FEDERAL COMMUNICATIONS COMMISSION

[CC Docket No. 92-237; DA 01-2593]

Next Meeting of the North American Numbering Council

AGENCY: Federal Communications Commission.

ACTION: Notice.

SUMMARY: On November 8, 2001, the Commission released a public notice announcing the November 27–28, 2001 meeting and agenda of the North American Numbering Council (NANC). The intended effect of this action is to make the public aware of the NANC's next meeting and its agenda.

FOR FURTHER INFORMATION CONTACT:

Deborah Blue, Special Assistant to the Designated Federal Officer (DFO) at (202) 418–2320 or dblue@fcc.gov. The address is: Network Services Division, Common Carrier Bureau, Federal Communications Commission, The Portals II, 445 12th Street, SW, Suite 6A207, Washington, DC 20554. The fax number is: (202) 418–2345. The TTY number is: (202) 418–0484.

SUPPLEMENTARY INFORMATION: Released: November 8, 2001.

The North American Numbering Council (NANC) has scheduled a meeting to be held Tuesday, November 27, 2001, from 8:30 a.m. until 5 p.m., and on Wednesday, November 28, 2001, from 8:30 a.m., until 12 noon (if required). The meeting will be held at the Federal Communications Commission, Portals II, 445 12th Street, SW, Room TW-C305, Washington, DC.

SUPPLEMENTARY INFORMATION: This meeting is open to members of the general public. The FCC will attempt to accommodate as many participants as possible. The public may submit written statements to the NANC, which must be received two business days before the meeting. In addition, oral statements at the meeting by parties or entities not represented on the NANC will be permitted to the extent time permits. Such statements will be limited to five minutes in length by any one party or entity, and requests to make an oral

statement must be received two business days before the meeting. Requests to make an oral statement or provide written comments to the NANC should be sent to Deborah Blue at the address under FOR FURTHER INFORMATION CONTACT, stated above.

Proposed Agenda

- 1. Announcements and Recent News
- 2. Approve Minutes
 - -Meeting of October 16-17, 2001
- 3. Report of North American Numbering Plan Administrator (NANPA)
- 4. Report of NANPA Oversight Working Group
- 5. Report of National Thousands-Block Pooling Administrator
- 6. Report of NANP Expansion/ Optimization IMG
- 7. Status of Industry Numbering Committee activities
- 8. Report of the Local Number Portability Administration (LNPA) Working Group
 - —Wireless Number Portability Operations (WNPO) Subcommittee
 - 9. Report of NAPM LLC
 - 10. Report from NBANC
- 11. Report of Cost Recovery Working Group
 - 12. Steering Committee
 - —Table of NANC Projects
 - 13. Report of Steering Committee
 - 14. Action Items
- 15. Public Participation (5 minutes each)
- 16. Other Business

Wednesday, November 28, 2001 (if required)

- 17. Complete any unfinished Agenda Items
 - 18. Other Business

Federal Communications Commission.

Diane Griffin Harmon,

Acting Chief, Network Services Division, Common Carrier Bureau.

[FR Doc. 01–28452 Filed 11–13–01; 8:45 am] BILLING CODE 6712–01–P

FEDERAL RESERVE SYSTEM

Meeting; Sunshine Act

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11 a.m., Monday, November 19, 2001.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551. STATUS: Closed.

MATTERS TO BE CONSIDERED:

- 1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
- 2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Michelle A. Smith, Assistant to the Board: 202–452–3204.

supplementary information: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: November 9, 2001.

Robert deV. Frierson,

 $Deputy\ Secretary\ of\ the\ Board.$

[FR Doc. 01–28600 Filed 11–9–01; 11:33 am]

BILLING CODE 6210-01-P

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans #	Acquiring	Acquired	Entities
TRANSACTIONS GRANTED EARLY TERMINATION—10/01/2001			
20012387	Fortis (B)	Protective Life Corporation	Protective Life Insurance Company.
20012442	Adventist Health System Sunbelt	PorteCare Adventist Health System	PorteCare Adventist Health System.
00040444	Healthcare Corporation.		
20012444	Constellation Brands, Inc	Derek Benham	Codera Production Group, LLC. Codera Wine Group, Inc
20012445	BRL Hardy Ltd	Derek Benham	Coderal Production Group, LLC.
	-		Coderal Wine Group, Inc
20012449	Constellation Brands, Inc	Courtney Benham	Codera Production Group, LLC. Codera Wine Group, Inc
20012450	BRL Hardy Ltd	Courtney Benham	Codera Production Group, LLC.
			Codera Wine Group, Inc.
20012461	Hewlett-Packard Company	Indigo N.V	Indigo N.V.
TRANSACTIONS GRANTED EARLY TERMINATION—10/04/2001			
20012303	Trinity Industries, Inc	Thrall Car Management Company, Inc	Thrall Car Manufacturing Company.
20012304	Thrall Car Management Company, Inc	Trinity Industries, Inc	Trinity Industries, Inc.
20012419	Capital One Financial Corporation	PeopleFirst Inc	PeopleFirst Inc.
20012452	NTELOS Inc	Conesoga Enterprises, Inc	Conestoga Enterprises, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—10/05/2001			
20012405	American Water Works Company, Inc	Enron Corp	Azurix Industries Corp.
20012406	American Water Works Company, Inc	Marlin Water Trust	Azurix North America Corp. Azurix Industries Corp.
00040447			Azurix North America Corp
20012447 20012465	Joseph Littlejohn & Levy Fund III, L.P Warburg Pincus Private Equity VIII L.P	LaQuinta Properties, IncMSN Holdings, Inc	Meditrust Healthcare Corporation. MSN Holdings, Inc.
20012465	GS Capital Partners 2000, L.P.	Apple American Midwest, Inc.	Apply American Limited Partnership o
20012470	CO Capital i artifera 2000, E.i	Apple American Midwest, me	Indiana.
			Apple American Limited Partnership of Ohio.
20012472	Madison Dearborn Capital Partners IV,	Focal Communications Corporation	Focal Communications Corporation.
00040400	L.P.	Constant A. Nicola	Aleksons Marshaus Isra
20012483	Verizon Communications Inc	Gregory A. Neely	Alabama Wireless, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—10/09/2001			
20012404	Fisher Scientific International Inc	Cole-Parmer Instrument Company	Cole-Parmer Instrument Company.
20020003	Marriott International, Inc	Scottish Power plc	Birmingham Syn Fuel I, Inc.
			Birmingham SynFuel II, Inc.
			Brimingham SynFuel, LLC.
			PacificCorp Financial Services, Inc. PacificCorp SynFuel, LLC.
	TRANSACTIONS OR	ANTER EARLY TERMINATION 40/40/00	
		ANTED EARLY TERMINATION—10/10/20	
20012178	Koninklijke Philips Electronics N.V	Marconi plc	Marconi Medical Systems, Inc.
20012460 20012484	ESL Partners, L.P Cadbury Schweppes plc	AutoNation, IncPernod Ricard S.A	AutoNation, Inc. Yoo-Hoo Industries Inc.
20012404	, ,, ,		
TRANSACTIONS GRANTED EARLY TERMINATION—10/11/2001			
20012468	H&CB	Kookmin Bank	Kookmin Bank.
20012469	Kookmin Bank	H&CB	H&CB Elan Pharma International Limited.
20012474 20012477	Ivax CorporaitonWarburg, Pincus Ventures, L.P	BEA Systems, Inc	BEA Systems, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—10/12/2001			
20012427			
20012437	Deutsche Telekom AG	NTELOS Inc	NTELOS Acquisition Corp., Conestoga Wireless Company.
20012448	CSR Limited	Cemex, S.A. de C.V	Cemex, S.A. de C.V.
20012451	Curtiss-Wright Corporation	Lau Massachusetts Business Trust	Lau Defense Systems, LLC.
20012454	Smithfield Foods, Inc	Packerland Holdings, IncSBC Communications Inc	Packerland Holdings, Inc.
20012482 20020002	Tyco International LtdAT&T Wireless Services, Inc	MetroPCS, Inc	Alarm Holdings, Inc. GWI PCS8, Inc., PCS81, LLC.
	ATAT WITCHOSS OFFWICES, ITIC	wiction CO, mic	5771 550, IIIC., 1 5501, LLC.

Competition, Room 303, Washington, DC 20580, (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 01–28446 Filed 11–13–01; 8:45 am] BILLING CODE 6750–01–M

FEDERAL TRADE COMMISSION

[File No. 012 3051]

A&S Pharmaceutical Corporation; Analysis To Aid Public Comment

AGENCY: Federal Trade Commission. **ACTION:** Proposed consent agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the complaint that accompanies the consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before December 6, 2001.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Ave., NW., Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Joni Lupovitz or Laura Koss, FTC/S-4302, 600 Pennsylvania Ave., NW., Washington, DC 20580. (202) 326-3743 or 326-2890.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46 and section 2.34 of the Commission's Rules of Practice (16 CFR 2.34), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC homepage (for November 6, 2001), on the World Wide Web, at http://www.fc.gov/os/2001/11/ index.htm. A paper copy can be obtained from the FTC Public Reference Room, Room H-130, 600 Pennsylvania Avenue, NW., Washington, DC 20580, either in person or by calling (202) 326-3627.

Public comment is invited. Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Ave., NW., Washington, DC 20580. Two paper copies of each comment should be filed, and should be accompanied, if possible, by a 3½ inch diskette containing an electronic copy of the comment. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with Section 4.9(b)(6)(ii) of the Commission's Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission has accepted an agreement, subject to final approval, to a proposed consent order from respondent A&S Pharmaceutical Corporation ("A&S").

The proposed consent order has been placed on the public record for thirty (30) days for reception of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the agreement and the comments received and will decide whether it should withdraw from the agreement and take other appropriate action or make final the agreement's proposed order.

This matter concerns ''Made in U.S.A" claims on packaging and labeling for A&S's aspirin tablets sold at retail bearing private brand names. The Commission's complain alleges that respondent misrepresented on packaging and labeling that certain of these products, manufactured for customers such as Food Lion, Price Chopper, and BJ's Wholesale Club, are all or virtually all made in the United States. According to the complaint, these products are actually made with significant foreign content. The products' active ingredient, bulk aspirin compound, that respondent processed into aspirin tablets is or was made outside the United States. The imported bulk aspirin compound comprises a substantial percentage of total manufacturing costs and imparts the crucial analgesic quality to the OTC products at issue. The Commission's complaint does not allege that all of A&S's private label aspirin brands or products are mislabeled, but only that certain products for certain customers have been improperly labeled.

The proposed consent order contains a provision that is designed to remedy the charges and to prevent the respondent from engaging in similar acts and practices in the future. Part I of the proposed order prohibits A&S from

misrepresenting the extent to which any over-the-counter drug product is made in the United States. The proposed order would allow A&S to represent that such products are made in the United States as long as all, or virtually all, of the ingredients or component parts of such products are made in the United States and all, or virtually all, of the labor in manufacturing such products is performed in the United States.

Part II of the proposed order requires the respondent to maintain materials relied upon in disseminating any representation covered by the order. Part III of the proposed order requires the respondent to distribute copies of the order to certain company officials and employees. Part IV of the proposed order requires the respondent to notify the Commission of any change in the corporation that may affect compliance obligations under the order. Part V of the proposed order requires the respondent to file one or more compliance reports. Part IV of the proposed order is a provision whereby the order, absent certain circumstances, terminates twenty years from the date of

The purpose of this analysis is to facilitate public comment on the proposed consent order. It is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way their terms.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 01–28441 Filed 11–13–01; 8:45 am] BILLING CODE 6750–01–M

FEDERAL TRADE COMMISSION

[File No. 012 3039]

Leiner Health Products, Inc.; Analysis To Aid Public Comment

AGENCY: Federal Trade Commission. **ACTION:** Proposed consent agreement.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair or deceptive acts or practices or unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the complaint that accompanies the consent agreement and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before December 6, 2001.